ClinicalTrials.Veeva

Menu

Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and Influenza

Azidus logo

Azidus

Status and phase

Not yet enrolling
Phase 3

Conditions

Covid 19
Influenza

Treatments

Drug: Nitazoxanide 600Mg Oral Tablet / placebo oral tablet

Study type

Interventional

Funder types

Industry

Identifiers

NCT06817096
FQMNita

Details and patient eligibility

About

  1. Participants will:
  • Take nitazoxanide 600mg (or placebo) orally twice daily for 7 days, for a total of 14 doses.
  • Visit the clinic on the 7th day of treatment for a check-up and safety tests.
  • Keep a diary of their symptoms and other medications used

Enrollment

340 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Signed informed consent form;
  • Male or female;
  • Age ≥ 18 years;
  • COVID-19 or influenza diagnosed by rapid test, with symptom onset less than 48 hours ago;
  • Clinical condition compatible with outpatient treatment.

Exclusion criteria

  • Known hypersensitivity to nitazoxanide;
  • History of cardiomyopathies, hepatopathies, or nephropathies;
  • Antineoplastic treatment with chemotherapy or radiotherapy;
  • Severe autoimmune diseases with immunosuppression;
  • Transplant recipients;
  • Any uncompensated systemic disease at the investigator's discretion;
  • Participation in clinical studies in the last 12 months;
  • Pregnant or breastfeeding individuals;
  • Suspected bacterial coinfection or prescription of antibiotic therapy at enrollment;
  • Diagnosis of neurological disease (traumatic brain injury, stroke, Parkinson's disease, Alzheimer's disease, other dementias);
  • Diagnosis of developmental disorder (ADHD, ASD, learning disabilities, intellectual disability, Rett syndrome);
  • Significant hearing or vision impairment.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

340 participants in 2 patient groups, including a placebo group

placebo
Placebo Comparator group
Description:
take placebo orally, twice daily for 7 days.
Treatment:
Drug: Nitazoxanide 600Mg Oral Tablet / placebo oral tablet
nitazoxanide
Experimental group
Description:
take nitazoxanide 600 mg orally, twice daily for 7 days
Treatment:
Drug: Nitazoxanide 600Mg Oral Tablet / placebo oral tablet

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems